Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX005N in adolescents with moderate-to-severe atopic dermatitis
ChiCTR2400082755Phase 2Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QX005N in atopic dermatitis (AD) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoints: Frequency and severity of adverse events and serious adverse events, Treatment discontinuation due to treatment-emergent adverse events and 3 more. Started Apr 2024; status: recruiting.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2400082755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082755.